Corporate transactions

  • Advising Société Générale on its acquisition of Shine, a French fintech and neobank dedicated to entrepreneurs.
  • Advising Société Générale on its acquisition of Treezor, a French fintech with pioneering Banking-as-a-Service platforms, providing services across the entire payment chain through API to many innovative financial-sector companies.
  • Advising ALD Automotive (part of the Société Générale group) on its joint-venture with Mitsubishi, establishing a multi-brand, full service operational leasing and fleet management business for corporate clients in Malaysia, this strategic partnership should facilitate the group’s development in all the key markets of South East Asia.
  • Advising ALD Automotive on its acquisition of SternLease BV in the Netherlands, the leasing arm of Stern Group, the Dutch listed market leader in automotive retail.
  • Advising ALD Automotive on its acquisition of Reflex Alquiler Flexible de Vehiculos in Spain.
  • Advising AON on a number of acquisitions, including the acquisition of Apollo Conseil & Courtage, a specialist broker providing insurance to companies operating in new technologies, the acquisition of Chapka Assurances, a specialist broker of online travel insurance, the acquisition of Ovatio, a specialist broker in entertainment risk management.
  • Advising Coca-Cola in the context of its acquisition of Tropico.
  • Advising Alcatel-Lucent on a number of matters including: the sale of its cyber security and legal interception businesses to Thales; the sale of its worldwide RFS business to Alcatel Shanghai Bell (China); the sale of its EUR200 million sale of its worldwide Adixen business to Pfeiffer; and the EUR145 million sale of its worldwide Dunkermotoren business to Triton and on its acquisition of Velocix.
  • Advising Allianz on the transnational merger of its French affiliates with German parent company.
Life Sciences transactions

Sonia de Kondserovsky has been the lead lawyer with respect to the following transactions:

  • Advising Groupe Pierre Fabre, an international pharmaceutical and dermo-cosmetic group, on its sale to Fareva of two manufacturing sites, specialized in development, manufacturing, and subcontracting of small scale biotechnology products (with a focus on monoclonal antibodies and antibody drug conjugate active pharmaceutical ingredients) and small scale batches of fill-and-finish sterile injectables, the transaction included several spin-offs to newly created entities.
  • Advising Groupe Pierre Fabre, on its strategic collaboration with Foresee regarding R&D and industrial development of pre-filled syringe products.
  • Advising Japan-based global pharmaceutical group Santen Pharmaceutical Co., Ltd. several transactions, including on its purchase of rights for ophthalmic drugs in Japan, Asia/Pacific and Europe from Merck & Co. for USD600 million and on its public tender offer on Novagali (Euronext C) and subsequent squeeze out.
  • Advising a major French pharmaceuticals group on various transactions, including the sale of its Quétigny manufacturing site, the USD300 million sale of worldwide marketed products to a US pharmaceutical group; several spinoffs to private equity funded joint-venture companies, followed by a majority holding held by a syndicate of investors; a USD315 million collaboration and license agreement with a Japanese laboratory, and the split and sale of several product manufacturing sites.
  • Advising Becton Dickinson on its French corporate restructuring in the context of the transfer of its respiratory solutions business to Vyaire Medical, a newly created joint venture.
  •  Advising Terumo Corporation on its acquisition of Bolton Medical SAS.
  • Advising Nordic Pharma on its strategic collaboration and license with Nippon Kayaku on Spanidin® (gusperimus) in selected territories outside Japan, including Europe.
  • Advising Innothéra on its strategic partnership with Bioserenity for the R&D and industrial development of connected medical devices.